We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Sabra (SBRA) Q4 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Sabra Healthcare (SBRA - Free Report) to post quarterly earnings of $0.36 per share in its upcoming report, which indicates a year-over-year increase of 9.1%. Revenues are expected to be $183.22 million, up 12.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.9% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Sabra metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Interest and other income' will reach $9.71 million. The estimate points to a change of +6.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Resident fees and services' will likely reach $75.05 million. The estimate indicates a change of +22.5% from the prior-year quarter.
Analysts expect 'Revenues- Rental and related revenues' to come in at $96.34 million. The estimate indicates a year-over-year change of +3.5%.
According to the collective judgment of analysts, 'Depreciation and amortization' should come in at $43.11 million. The estimate is in contrast to the year-ago figure of $42.88 million.
Over the past month, shares of Sabra have returned -2.5% versus the Zacks S&P 500 composite's +4.7% change. Currently, SBRA carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Sabra (SBRA) Q4 Earnings: Wall Street Estimates for Key Metrics
Wall Street analysts expect Sabra Healthcare (SBRA - Free Report) to post quarterly earnings of $0.36 per share in its upcoming report, which indicates a year-over-year increase of 9.1%. Revenues are expected to be $183.22 million, up 12.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.9% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Sabra metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Interest and other income' will reach $9.71 million. The estimate points to a change of +6.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Resident fees and services' will likely reach $75.05 million. The estimate indicates a change of +22.5% from the prior-year quarter.
Analysts expect 'Revenues- Rental and related revenues' to come in at $96.34 million. The estimate indicates a year-over-year change of +3.5%.
According to the collective judgment of analysts, 'Depreciation and amortization' should come in at $43.11 million. The estimate is in contrast to the year-ago figure of $42.88 million.
View all Key Company Metrics for Sabra here>>>
Over the past month, shares of Sabra have returned -2.5% versus the Zacks S&P 500 composite's +4.7% change. Currently, SBRA carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>